Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Phase 3 Recruiting 1594 enrolled European Myeloma Network B.V. Janssen Pharmaceutica · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.

Timeline

Start: 2022-09-08
Primary completion: 2028-04
Completion: 2032-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lenalidomide	Other / unclassified	—	Oral
Subject	Teclistamab	Monoclonal antibody	—	Subcutaneous

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Summary

Timeline

Drugs

Indications